Gilead Sciences Acquires Nimbus Apollo for $400M

Gilead Sciences, Inc. GILD and Nimbus Therapeutics announced Monday that the companies have signed a agreement to acquire Nimbus Apollo, Inc., a subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program. Nimbus Therapeutics will receive an upfront payment of $400 million, with the potential to receive an additional $800 million in development-related milestones over time. Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer of Gilead Sciences commented "The acquisition of Nimbus' ACC-inhibitor program represents a timely and important opportunity to accelerate Gilead's ongoing efforts to address unmet needs in NASH." Shares of Gilead Sciences are down 0.09 percent today.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!